Hot Biotech Stocks To Buy For 2021

Utility stocks were among the worst-performing sectors of the market earlier this year, but theyre making a roaring comeback.

The utilities-tracking XLU ETF has risen in 13 of the last 14 trading sessions, jumping 10 percent in one month alone. Gina Sanchez, CEO of Chantico Global, told CNBCs Trading Nation on Friday that the run is likely to continue as investors retreat into more stable sectors. Here are her reasons why.

Utilities had taken a backseat to more growth-oriented stocks like technology amid broad economic expansion and the prospect of higher interest rates that could theoretically depress utilities prices. Now, as the market is turning more defensive and a U.S.-China trade tiff has come into focus, utilities look more attractive.

Utilities typically pay substantial dividend yields; the XLU carries a yield of 3.3 percent, and some names within the group pay out even heftier dividends relative to the market.

Hot Biotech Stocks To Buy For 2021: Amgen Inc.(AMGN)

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Every so often on Rule Breaker Investing, Motley Fool co-founder David Gardner shares a five-stock sampler — five active recommendations in either Rule Breakers or Stock Advisor that are poised for great things. This week: five healthcare companies that are innovating treatments and drugs that are making the world healthier. Learn more about Amgen (NASDAQ:AMGN), bluebird bio (NASDAQ:BLUE), Editas Medicine (NASDAQ:EDIT), Illumina (NASDAQ:ILMN), and Vertex Pharmaceuticals (NASDAQ:VRTX) and why you should add these exciting and inspiring stocks to your watch list.

  • [By ]

    Even though ABBV has more than 100 patents covering Humira, and despite its 2017 patent win over Amgen (Nasdaq: AMGN) requiring AMGN to wait until 2023 before issuing its own copy of Humira, the battle for generic Humira isn’t over.

Hot Biotech Stocks To Buy For 2021: Alnylam Pharmaceuticals Inc.(ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit

  • [By Cory Renauer]

    Staying on top of every new drugmaker takes a lot more time than you probably have. That said,Alnylam Pharmaceuticals (NASDAQ:ALNY)andPfizer (NYSE:PFE) shareholders want to keep their eyes on young Eidos and its lead candidate. Here’s why.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) updated investors last month on how the launch of Onpattro, its first drug that was approved to treat transthyretin-mediated amyloidosis (ATTR), was going at the J.P. Morgan Healthcare Conference.

Hot Biotech Stocks To Buy For 2021: Biogen Idec Inc(BIIB)

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer’s disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.

Advisors’ Opinion:

  • [By ]

    Just last Thursday, March 21, Biogen (Nasdaq: BIIB) and its partner, Japanese biopharmaceutical company Eisai (OTC: ESALY), said that their experimental Alzheimer’s therapy, which at that time was at the second stage of clinical trials, was a bust. BIIB dropped 29.2% on the day, and ESALY by 35% on the same day.

  • [By Chris Hill]

    In this episode ofMotley Fool Money, host Chris Hill and analysts Emily Flippen, Jim Mueller, and Jason Moser hit on some of the biggest recent news in the market. Disney (NYSE:DIS)finishes up its merger with Fox, and it’s ready to take on a crowded streaming space. CVS Health(NYSE:CVS) diversifies into CBD lotion. Levi Strauss(NYSE:LEVI) enters the public markets with a bafflingly high market cap, while Nike (NYSE:NKE)sells off on higher-than-expected revenue and profits. Biogen’s (NASDAQ:BIIB) biggest trial bombs, and the stock tanks along with it. Papa John’s(NASDAQ:PZZA) welcomes Shaq into its board of directors. And, as always, the analysts share some stocks on their radar. Plus, stay tuned for an interview with Lake House Capital’s Joe Magyer about investing in Australia — the biggest trends, biggest worries, and some Aussie picks to add to your watch list.

  • [By Garrett Baldwin]

    Nike Inc. (NYSE: NKE) will lead a busy day of earnings reports. The firm expects that its year-over-year sales will have increased by 7%. The company’s stock slumped in February after Duke basketball player Zion Williamson was hurt blowing out his sneaker in the first minute of a major contest against North Carolina. Expect analysts to ask a lot of questions about Nike’s expectations for global economic growth and its exposure to a weakening Chinese economy.
    Stocks to Watch Today: BIIB, BA, LEVI
    Shares of Biogen Inc.(NASDAQ: BIIB) plunged more than 25% after the company announced a major setback for a key Alzheimer’s drug. The biotech giant announced that its experimental drug “aducanumab” is unlikely to be effective for mass deployment and that it will halt its research. One analyst described this as a “transformative failure for Biogen’s pipeline.” This is a massive setback for one of the top biotech companies in the world. Shares of Boeing Co. (NYSE: BA) are off again Thursday on news that the investigation into its 737 Max jets has expanded. According to reports, the FBI has now joined a federal investigation into the certification process for the jet. The Department of Transportation launched an audit of the Federal Aviation Administration’s approval of the jet, which received certification two years ago. Boeing and the FAA have faced global scrutiny over two fatal crashes involving the 737 Max jet series and news of previous pilot complaints about the planes. Levi Strauss & Co. (NYSE: LEVI) will return to the public markets for the first time in 34 years. The iconic apparel company will launch its IPO today with a price of $17 per share. That would set the company’s market capitalization at $6.6 billion. Look for other earnings reports from Canadian Solar Inc. (NASDAQ: CSIQ), Cintas Corp. (NASDAQ: CTAS), CNOOC Ltd. (NYSE: CEO), Conagra Brands Inc. (NYSE: CAG), Darden Restaurants Inc. (NYSE: DRI), and Lands’ End Inc. (NYSE: LE).
    Public Law 92-

  • [By Money Morning News Team]

    Biogen Inc. (NASDAQ: BIIB) is a Massachusetts-based company that focuses on discovering, developing, manufacturing, and delivering therapies for neurodegenerative and neurological diseases worldwide.

Hot Biotech Stocks To Buy For 2021: ArQule Inc.(ARQL)

ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product ARQ 197 is non-adenosine triphosphate competitive inhibitor of the c-Met receptor tyrosine kinase, which is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in non-small cell lung cancer, c-Met-associated soft tissue sarcomas, pancreatic adenocarcinoma, hepatocellular carcinoma, germ cell tumors, and colorectal cancer. The company is also developing ARQ 621, a Phase I program focused on inhibition of the Eg5 kinesin spindle protein. Its clinical stage products include ARQ 501, ARQ 761, and ARQ 171, which are designed to kill cancer cells selectively while sparing normal cells through the direct activation of DNA damage response/checkpoint pathways. In addition, the company involves in pre-clinical development o f B-RAF and AKIP Kinase inhibitors. The company has collaborations with Kyowa Hakko Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

Advisors’ Opinion:

  • [By Cory Renauer]

    It isn’t unusual for oncology stocks to double in a single day after a company announces clinical trial results. Arqule (NASDAQ:ARQL) stands out among its peers because it notched a 67% gain after reporting a partial remission for just one leukemia patient.

  • [By Motley Fool Transcribers]

    Arqule Inc (NASDAQ:ARQL)Q42018 Earnings Conference CallMarch 07, 2019, 9:00 a.m. ET

    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:


Top 5 Undervalued Stocks To Own Right Now

How Trump’s Tax Act Could Affect Annuity Issuers

5 Big Questions About Life Insurance for 2018

How to Lean Against the Biases in 2018

Trinity Place Holdings Inc. has closed on $189.5 million in construction financing for its new 300,000-square-foot mixed-use development at 77 Greenwich St. in Lower Manhattan, in New York City.

The project calls for the construction of an approximately 500-foot tall tower building that will contain 90 luxury condominium units, the adaptive reuse of the landmarked Robert and Anne Dickey House, 7,500 square feet of street level retail space, and construction of a new wheelchair-accessible subway entrance on Trinity Place.

The construction loan has a four-year term with one extension option. The loan, in addition to equity already funded by Trinity Place and future contributions by the New York City School Construction Authority, will cover anticipated future costs of the project. The project hard costs are 93% “bought out” and are managed under a gross maximum price construction contract, Trinity Place reports. In its press announcement, Trinity did not provide any further financial details of the transaction, including the identity of the lender.

Top 5 Undervalued Stocks To Own Right Now: Ecolab Inc.(ECL)

Ecolab was incorporated as a Delaware corporation in 1924. Our fiscal year is the calendar year ending December 31.

In 2015, we took several actions to continue to invest in and build our business, including: the June 2015 acquisition of Jianghai Environmental Protection Co. Ltd, an industrial water treatment company headquartered in Changzhou, China; the November 2015 acquisition of the U.S. operations of Charlotte, N.C. – based Swisher Hygiene Inc, a provider of hygiene and sanitizing solutions for the foodservice, hospitality, retail and healthcare markets; and the November 2015 acquisition of the assets and operations of Calgary – based Ultra Fab Industries Ltd, which manufactures customized solutions and specialized chemical injection systems for the oil and gas industry. See Part II, Item 8, Note 4 of this Form 10-K for additional information about these three acquisitions as well as additional actions taken by the Company.   Advisors’ Opinion:

  • [By Ethan Ryder]

    TRADEMARK VIOLATION WARNING: “Ecolab (ECL) Sets New 52-Week High at $173.40” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at

  • [By Maxx Chatsko]

    Last year,Ecolab (NYSE:ECL) had to navigate headwinds including global currency fluctuations made worse by a strong U.S. dollar, rising delivery costs, and volatility in energy markets. The business attempted to offset cost increases by improving operating efficiency and increasing selling prices, but those efforts weren’t enough to stop fourth-quarter operating income from sliding 4% compared to 2017. Revenue increased 3% year over year.

  • [By Motley Fool Transcription]

    Ecolab Inc. (NYSE:ECL)Q4 2018 Earnings Conference CallFebruary 19, 2019, 1:00 p.m. ET

    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:


Top 5 Undervalued Stocks To Own Right Now: CIM Commercial Trust Corporation(CMCT)

CIM Commercial Trust Corporation (CIM Commercial), incorporated on April 25, 2014, is engaged in acquiring, owning and operating Class A office investments in urban communities throughout the United States. These communities are located in areas that include traditional downtown areas and suburban main streets. The Company operates in the business segments, including the acquisition, redevelopment, ownership and management of office real estate, multifamily real estate and hotels. The Company’s real estate portfolio consists of approximately 30 assets, all of which are fee-simple properties except one leasehold property. It has approximately 20 office properties (including over two parking garages, one of which has street level retail space, and over two development sites, one of which is being used as a parking lot), totaling approximately 5.6 million rentable square feet, which are approximately 86.9% occupied; multifamily properties, composed of over 930 units, which are approximately 92.4% occupied, and hotels, which have a total of approximately 1,070 rooms. Its office, multifamily and hotel assets are located in over 10 of the United States markets. The Company is managed by affiliates of CIM Group, L.P. (CIM Group or CIM).

The Company seeks risk adjusted returns by utilizing the CIM platform. The Company invests primarily in substantially stabilized real estate and real estate related assets located in areas that CIM has targeted for opportunistic investment. CIM targets investments in diverse types of real estate assets, including office, retail, for rent and for sale multifamily residential, hotel, parking, and signage through CIM’s network and its opportunistic investment activities.

Advisors’ Opinion:

  • [By Logan Wallace]

    Crowd Machine (CURRENCY:CMCT) traded down 3.1% against the U.S. dollar during the 1-day period ending at 18:00 PM ET on February 2nd. One Crowd Machine token can currently be bought for approximately $0.0023 or 0.00000066 BTC on major cryptocurrency exchanges including Bancor Network, BitForex, Bittrex and HitBTC. During the last seven days, Crowd Machine has traded down 41.4% against the U.S. dollar. Crowd Machine has a total market capitalization of $1.09 million and approximately $553,701.00 worth of Crowd Machine was traded on exchanges in the last day.

  • [By Shane Hupp]

    CIM Commercial Trust (NASDAQ:CMCT) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

  • [By Joseph Griffin]

    Crowd Machine (CURRENCY:CMCT) traded 9.6% lower against the US dollar during the 24-hour period ending at 0:00 AM ET on May 14th. Over the last week, Crowd Machine has traded down 49% against the US dollar. One Crowd Machine token can now be bought for approximately $0.0436 or 0.00000499 BTC on exchanges including Coinhub, BitForex and HitBTC. Crowd Machine has a market capitalization of $0.00 and $233,116.00 worth of Crowd Machine was traded on exchanges in the last 24 hours.

  • [By Jack Delaney]

    CIM Commercial Trust Corp. (NYSE: CMCT) acquires, owns, and operates office properties in the United States.

    It has a portfolio of more than 100 buildings that is valued at a combined $25 billion, according to

Top 5 Undervalued Stocks To Own Right Now: Pagegroup PLC (PAGE)

PageGroup plc, formerly Michael Page International plc, is a United Kingdom-based recruitment consultancy. The Company’s segments include EMEA, United Kingdom, Asia Pacific and Americas. The Company is organized into three brands operating at different levels of the market: Michael Page, Page Personnel and Page Executive. Page Executive offers executive search services. Page Executive provides a range of search, selection and management solutions for organizations on a permanent and interim basis. Michael Page recruits on a permanent, temporary, contract, and interim basis from second/third job levels upward. Page Personnel offer specialist recruitment services to organizations requiring permanent employees or temporary or contract staff at technical and administrative support, professional clerical and junior management levels. The Company provides specialist services to organizations requiring talent at the professional clerical and support levels. Advisors’ Opinion:

  • [By Shane Hupp]

    Pagegroup (LON:PAGE) had its target price cut by equities researchers at Jefferies Financial Group from GBX 610 ($7.97) to GBX 590 ($7.71) in a note issued to investors on Tuesday, ThisIsMoney.Co.Uk reports. The firm presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 10.90% from the stock’s previous close.

  • [By Joseph Griffin]

    Pagegroup (LON:PAGE) had its target price reduced by Royal Bank of Canada from GBX 670 ($8.75) to GBX 620 ($8.10) in a note issued to investors on Monday. The firm presently has an “outperform” rating on the stock. Royal Bank of Canada’s price target would indicate a potential upside of 30.86% from the stock’s current price.

Top 5 Undervalued Stocks To Own Right Now: Fiserv, Inc.(FISV)

Fiserv, Inc. is a leading global provider of financial services technology. We are publicly traded on the NASDAQ Global Select Market and part of the S&P 500 Index. We serve approximately 14,500 clients worldwide, including banks, thrifts, credit unions, investment management firms, leasing and finance companies, retailers, and merchants. We provide account processing systems; electronic payments processing products and services, such as electronic bill payment and presentment services, card-based transaction processing and network services, ACH transaction processing, account-to-account transfers, and person-to-person payments; internet and mobile banking systems; and related services including document and payment card production and distribution, check processing and imaging, source capture systems, and lending and risk management products and services.   Advisors’ Opinion:

  • [By Billy Duberstein]

    In particular, Palmer worries about Fiserv’s (NASDAQ:FISV)recent acquisition of First Data (NYSE:FDC). First Data makes the Clover point-of-sale system, a Square competitor. The combined companies say they intend to spend over $500 million over five years to “accelerate growth,” which likely means putting serious weight behind Clover.

  • [By Shane Hupp]

    Fiserv (NASDAQ:FISV) last released its quarterly earnings data on Thursday, February 7th. The business services provider reported $0.84 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.84. Fiserv had a return on equity of 47.56% and a net margin of 20.39%. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.55 billion. During the same quarter in the previous year, the firm posted $0.71 EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. Equities analysts expect that Fiserv Inc will post 3.46 EPS for the current fiscal year.

    ILLEGAL ACTIVITY NOTICE: “Checchi Capital Advisers LLC Has $581,000 Position in Fiserv Inc (FISV)” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at

    Fiserv Profile

  • [By Max Byerly]

    Cerity Partners LLC reduced its stake in Fiserv Inc (NASDAQ:FISV) by 0.5% during the fourth quarter, HoldingsChannel reports. The firm owned 27,751 shares of the business services provider’s stock after selling 139 shares during the quarter. Cerity Partners LLC’s holdings in Fiserv were worth $2,039,000 as of its most recent SEC filing.

Top 5 Undervalued Stocks To Own Right Now: Jazz Pharmaceuticals Inc.(JAZZ)

Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products to meet unmet medical needs. The company markets Xyrem, a sodium oxybate oral solution for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR extended-release capsules for the treatment of obsessive compulsive disorder. Its product candidates under clinical development include JZP-6, a Phase III pivotal clinical trials completed product for the treatment of fibromyalgia; and JZP-8, an intranasal formulation of clonazepam, which has completed Phase II clinical trial for the treatment of acute repetitive seizures in epilepsy and solid oral dosage forms of sodium oxybate. The company sells its products through specialty sales force targeting sleep specialists, psychiatrists, neurologists, and pulmonologists. Jazz Pharmaceuticals, Inc. was founded in 2003 and is headq uartered in Palo Alto, California.

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

    For more information about research offerings from Zacks Investment Research, visit

  • [By Max Byerly]

    COPYRIGHT VIOLATION NOTICE: “Matthew P. Young Sells 1,152 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock” was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at

  • [By Keith Speights]

    The three best biotech bargains on the market right now based on PEG ratios are Celgene (NASDAQ:CELG), Exelixis (NASDAQ:EXEL), and Jazz Pharmaceuticals (NASDAQ:JAZZ). Here’s why these biotech stocks are priced attractively.